|Podcasts|June 22, 2023

Listening is the Key to Good Leadership

Author(s)Meg Rivers

HBA mentor of the year and director of U.S. public affairs for AbbVie, Jag Dosanjh, divulges in this Pharm Exec Podcast his approach to leadership and how: “If you listen well, you can learn well.”

We all know that the pharma industry is about people—bettering the lives of others through good research, life-changing pharmaceuticals, and keeping the patient front and center. But Jag Dosanjh, president of US neuroscience and eye care, AbbVie, lives that principle. In this podcast episode, Meg Rivers, managing editor, talks with Dosanjh about what he calls a “people business” and his approach to leadership. He starts his career in the medical sales space before working in many different roles and therapeutic areas before ultimately landing at AbbVie. He was also nominated HBA’s mentor of the year and shares insights into being a good leader and mentor. One of his tips was: “If you listen well, you can learn well.” In addition, he emphasized the importance of curiosity, learning, and the pursuit of a smile.


About the speaker

Jag Dosanjh is the president of US neuroscience and eye care, AbbVie, where he is responsible for leading the business and represents a strong portfolio of major brands across many different disease areas. Dosanjh joined AbbVie in 2011 and served in a variety of business leadership roles in addition to leading the U.S. market access and global strategic marketing functions. Most recently, he served as senior vice president of medical therapeutics, overseeing BOTOX therapeutic and eye care. Prior to this, Dosanjh worked at GlaxoSmithKline for more than 15 years in several executive positions in both European, U.S., and global roles with key areas of focus being vaccine biologicals and respiratory medicine. Dosanjh holds a BA (Hons) degree in business studies from Sheffield Hallam University in the UK.


About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.